ZPDC glycoprotein inhibits inflammation-related cytokine and protein via nuclear factor-kappa B in dextran sulfate sodium-stimulated ICR mouse.
The purpose of this study is to investigate the anti-inflammatory potentials of a 24-kDa glycoprotein isolated from Zanthoxylum piperitum DC fruit (ZPDC glycoprotein) in dextran sulfate sodium (DSS)-stimulated ICR mouse colitis. ZPDC glycoprotein was administered to mice at 10 and 20 mg/kg for 7 days and then the mice were co-treated with 5% DSS for another 7 days in presence of ZPDC glycoprotein and killed on day 15. The results showed that ZPDC glycoprotein has inhibitory effects on levels of disease activity index and large intestine shortening in DSS-treated mice. In addition, ZPDC glycoprotein suppresses the formation of thiobarbituric acid reactive substances, production of inducible nitric oxide, and release of lactate dehydrogenase in DSS-treated mice plasma. Interestingly, we found that consumption of ZPDC glycoprotein (20 mg/kg) significantly inhibited the expressions of interleukin-1beta and tumor necrosis factor-alpha, inducible nitric oxide synthase, and cyclooxygenase-2 via modulation of transcriptional activity of nuclear factor-kappa B in DSS-treated mice colon. Collectively, these results suggest that ZPDC glycoprotein is useful for prevention of inflammatory gastrointestinal diseases.
Lee
Sei-Jung
SJ
Molecular Biochemistry Laboratory, Biotechnology Research Institute and Center for the Control of Animal Hazards Using Biotechnology (BK 21), Chonnam National University, Kwangju 500-757, Republic of Korea.
Lim
Kye-Taek
KT
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D003092:Colitis / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D003106:Colon / Q000378:metabolism / Q000473:pathology; D051546:Cyclooxygenase 2 / Q000096:biosynthesis*; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D016264:Dextran Sulfate; D004305:Dose-Response Relationship, Drug; D005638:Fruit / Q000737:chemistry; D006023:Glycoproteins / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D016328:NF-kappa B / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D032106:Zanthoxylum / Q000737:chemistry*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D006023:Glycoproteins; D053583:Interleukin-1beta; D016328:NF-kappa B; D017392:Thiobarbituric Acid Reactive Substances; D014409:Tumor Necrosis Factor-alpha; D016264:Dextran Sulfate; D007770:L-Lactate Dehydrogenase; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2